B. Ghosh

发表

Immunolymphoscintigraphy and the dose dependence of 111In-labeled T101 monoclonal antibody in patients with cutaneous T-cell lymphoma.

J. Weinstein, S. Larson, P. Bunn, 1987, Cancer research.

Tumor cell lines established in vitro: an independent prognostic factor for survival in non-small-cell lung cancer.

A. Gazdar, D. Ihde, B. Ghosh, 1990, Annals of internal medicine.

Integrated clinical and basic studies related to circumventing non-small cell lung cancer drug resistance.

B. Kramer, J. Minna, A. Gazdar, 1994, Lung cancer.

The correct dose: pharmacologically guided end point for anti-growth factor therapy.

S. Larson, J. Mulshine, I. Avis, 1992, Cancer research.

Phase II trial of fludarabine phosphate and interferon alfa-2a in advanced mycosis fungoides/Sézary syndrome.

S. Steinberg, I. Linnoila, F. Foss, 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic implications of evaluation for lymph node involvement by T- cell antigen receptor gene rearrangement in mycosis fungoides

S. Steinberg, E. Sausville, E. Sausville, 1992 .

Prognostic implications of evaluation for lymph node involvement by T-cell antigen receptor gene rearrangement in mycosis fungoides.

S. Steinberg, E. Sausville, A. Fischmann, 1992, Blood.

Correlation of in vitro drug sensitivity testing results with response to chemotherapy and survival: Comparison of non‐small cell lung cancer and small cell lung cancer

S. Steinberg, J. Minna, A. Gazdar, 1996, Journal of cellular biochemistry. Supplement.

Individualized chemotherapy for patients with non-small cell lung cancer determined by prospective identification of neuroendocrine markers and in vitro drug sensitivity testing.

S. Steinberg, J. Minna, A. Gazdar, 1993, Cancer research.

Correlation of in vitro drug-sensitivity testing results with response to chemotherapy and survival in extensive-stage small cell lung cancer: a prospective clinical trial.

S. Steinberg, J. Minna, A. Gazdar, 1990, Journal of the National Cancer Institute.

Phase II study of pentostatin and intermittent high-dose recombinant interferon alfa-2a in advanced mycosis fungoides/Sézary syndrome.

I. Linnoila, F. Foss, J. Breneman, 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A dose intensity study of FLAC (5-fluorouracil, leucovorin, doxorubicin, cyclophosphamide) chemotherapy and Escherichia coli-derived granulocyte-macrophage colony-stimulating factor (GM-CSF) in advanced breast cancer patients.

D. Venzon, L. Pierce, J. O’Shaughnessy, 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

Adjuvant treatment of colorectal cancer

U. Metzger, B. Ghosh, B. Ghosh, 2004, Cancer Chemotherapy and Pharmacology.

Correlation of in vitro drug-sensitivity testing results with response to chemotherapy and survival in extensive-stage small cell lung cancer: a prospective clinical trial.

S. Steinberg, J. Minna, A. Gazdar, 1990, Journal of the National Cancer Institute.